Luteinizing Hormone-to-Follicle Stimulating Hormone Ratio
LH / FSH
Description
"Luteinizing Hormone (LH)-to-Follicle Stimulating Hormone (FSH) Ratio" test assesses the relationship between two key reproductive hormones. An imbalanced ratio may indicate conditions such as PCOS, infertility, or pituitary dysfunction. This test is especially helpful for individuals with irregular periods, delayed puberty, or trouble conceiving. Doctors analyze the ratio to guide diagnosis and determine next steps, such as hormone therapy or additional testing. Monitoring LH and FSH levels over time supports long-term hormonal health and personalized fertility management.
Test Category
Hormones
Procedure
Invasive
Sample Type
Blood – Serum
Units
Ratio
Procedure Category
Blood Draw
Test Group
Hormone Health Group, Complete Sex Hormone Group
Test Group Description
Complete Sex Hormone Group: This comprehensive panel offers an extensive evaluation of sex hormone status and reproductive health, providing detailed insights into hormonal balance and function. Hormone Health Group: Its focus is on evaluating hormone levels and function, providing insights into hormonal balance and associated health conditions.
Optimal Range
For All Individuals:
Conventional Unit: 1.0
SI Unit: Not Applicable
Normal Range
For All Individuals:
Conventional Unit: 1.0–2.0
SI Unit: Not Applicable
Results That Differ From The Norm (Direct and Indirect Causes)
Increased levels may indicate:
Chronic stress
Congenital adrenal hyperplasia (Genetic disorder affecting adrenal gland function)
Functional ovarian hyperandrogenism (Condition involving excessive androgen production in the ovaries)
Polycystic ovary syndrome (Hormonal disorder causing enlarged ovaries with small cysts)
Polycystic ovaries without PCOS (P...
Key Reasons For Testing
Ovulation Monitoring: Evaluates luteinizing hormone and follicle-stimulating hormone balance to optimize conception timing.
PCOS Diagnosis: Identifies polycystic ovary syndrome through elevated LH/FSH ratios.
HPG Axis Function Assessment: Reflects hypothalamus-pituitary-gonadal axis health for reproductive evaluations.
Menstrual Irregularities: Diagnoses and manages conditions like amenorrhea or irregular periods.
Prediction of Ovulation Disorders: Detects anovulation or luteal phase defects affecting fertility.
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Saadia Z. Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non-Obese Women. Med Arch. 2020;74(4):289-293.
[2] Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, eds. Polycystic Ovary Syndrome. Boston, MA: Blackwell Scientific; 1992:377-384.
[3] Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333(13):853-861.
[4] Azziz R, Carmina E, Dewailly D, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237-4245.
[5] Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-4592.
[6] Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16(4):347-363.
[7] Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and luteinizing hormone secretion in polycystic ovary syndrome. Hum Reprod. 2005;20(10):2801-2808.
[8] Gilling-Smith C, Story H, Rogers V, Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1997;47(1):93-99.
[9] Pehlivanov B, Mitkov M. Serum luteinizing hormone/follicle-stimulating hormone ratio in women with polycystic ovary syndrome. Folia Med (Plovdiv). 2009;51(4):56-63.
[10] Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004;60(1):1-17.
[11] Abdel-Rahman MY, Shalaby NM, Shalaby YM, Samy AK, El-Baky FA. Relationship between serum LH/FSH ratio and clinical, hormonal and metabolic disturbances in women with polycystic ovary syndrome. J Obstet Gynaecol Res. 2011;37(4):540-545.
[12] Chen X, Yang D, Mo Y, Li L, Chen Y, Huang Y. Prevalence of polycystic ovary syndrome in unselected women from a university hospital in southwest China. Eur J Obstet Gynecol Reprod Biol. 2008;139(1):59-64.
[13] Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82(7):2248-2256.
[14] Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med. 1992;327(3):157-162.